Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 12/20 | 0.72 |
| ▸ | CYP11B1 | P15538 | 12/20 | 0.72 |
| ▸ | NOTUM | Q6P988 | 7/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8239512 | 0.85 | CYP11B1 (0.82) | CYP11B2CYP11B1NOTUM | |
| SCHEMBL18148229 | 0.84 | CYP11B2 (1.00) | CYP11B2CYP11B1 | |
| SCHEMBL8486184 | 0.83 | CYP11B1 (0.56) | CYP11B2CYP11B1 | |
| SCHEMBL4740743 | 0.83 | CYP11B1 (0.63) | CYP11B2CYP11B1NOTUM | |
| SCHEMBL15638777 | 0.83 | CYP11B2 (1.00) | CYP11B2CYP11B1 | |
| SCHEMBL16989882 | 0.82 | CYP11B2 (1.00) | CYP11B2CYP11B1NOTUM | |
| SCHEMBL23187985 | 0.81 | CYP11B2 (0.76) | CYP11B2CYP11B1NOTUM | |
| SCHEMBL15639689 | 0.80 | CYP11B2 (1.00) | CYP11B2CYP11B1NOTUM | |
| SCHEMBL15639251 | 0.80 | CYP11B2 (1.00) | CYP11B2CYP11B1NOTUM | |
| SCHEMBL6394572 | 0.80 | HSD17B3 (0.71) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| CN-101253152-A | Amide derivatives as ROCK inhibitors | ASTELLAS PHARMA INC (JP) | 2008-08-27 | — | — | CN | disclosed |
| EP-1922306-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007026920-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | CYP11B2 911/4885CYP11B1 971/4885NOTUM 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.